Clinical Study
Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment
Table 2
EULAR responses at next reevaluation after first RA flare.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differences between EULAR responses in group A and group B were tested using Kruskal-Wallis test, for each biologic agent. RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab. Group A: detectable drug level; Group B: undetectable drug level. |